Bisoprolol Production Cost Reports

The report provides detailed analysis essential for establishing a bisoprolol production plant. It encompasses all critical aspects necessary for bisoprolol production, including the cost of bisoprolol production, bisoprolol plant cost, bisoprolol production costs, and the overall bisoprolol production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a bisoprolol production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Bisoprolol Market Analysis: Demand and Supply Analysis, and Sourcing

Bisoprolol is a cardioselective beta-blocker that slows the heart and lowers blood pressure by blocking beta-1 adrenergic receptors. It is generally sold as bisoprolol fumarate, a salt of two base molecules and one molecule of fumaric acid. E. Merck of Darmstadt, now Merck KGaA, patented the molecule in 1976. Patients first received it in 1986 under the Concor brand, and the US approved it in 1992, when it launched as Zebeta. Bisoprolol is on the WHO List of Essential Medicines. Its beta-1 selectivity runs well above that of atenolol, metoprolol, or betaxolol, which suits patients with asthma, diabetes, or peripheral vascular disease.

Demand for bisoprolol is largely driven by hypertension, chronic heart failure, stable angina, and heart-rate control. Europe is its strongest market, where it ranks among the most widely prescribed beta-blockers. In the US, it is around 220th among prescribed drugs, with more than one million prescriptions a year. Patent protection lapsed long ago, so nearly all volume now moves as low-cost generics. Daily doses run from 1.25 mg to 10 mg, so a very large patient base, spread across clinics, hospitals, and pharmacies, needs only a modest tonnage of API.

Buyers of bisoprolol fumarate are generic tablet makers in Europe, India, Latin America & the Middle East, along with Merck for its own Concor range. About a dozen sites hold a European Certificate of Suitability for the API, with most in India and others in Spain, Germany, China & Taiwan. A bisoprolol demand and supply analysis has to analyze heart-failure prevalence, aging populations, tender pricing, and the number of qualified sources. On receipt, buyers check HPLC assay, related substances, fumaric acid content, water, residual solvents, and N-nitroso bisoprolol.

Summary of the Product, Grades, and Uses

Bisoprolol base has the molecular formula C18H31NO4 and a molar mass of 325.44 g/mol under CAS 66722-44-9. Bisoprolol fumarate, the commercial salt, is (C18H31NO4)2·C4H4O4 with a molar mass of 766.96 g/mol under CAS 104344-23-2. Structurally, bisoprolol belongs to the aryloxypropanolamine class of beta-blockers. A phenol ring carries an isopropoxyethoxymethyl side chain at one end and the isopropylamino propanol arm typical of beta-blockers at the other. The molecule has one stereocenter and is sold as the racemate. The fumarate is a white, crystalline, odorless powder that melts near 100 degree Celsius and dissolves readily in water, methanol & ethanol.

Bisoprolol fumarate API is marketed in compliance with Ph. Eur., USP, and JP monographs. The USP limits call for 97.5 to 102.0 percent assay on the anhydrous basis, total impurities at or below 0.5 percent, water at or below 0.5 percent, and fumaric acid between 14.8 and 15.4 percent. Many makers offer milled or controlled particle-size grades, since the low tablet dose demands good content uniformity. Reference standards, impurity standards, and stable-labeled internal standards form a small analytical grade. Bisoprolol free base serves a specialized market in Japan, where it goes into a transdermal patch.

The vast majority of bisoprolol consumption is in oral tablet formulations for hypertension, heart failure & angina, and arrhythmia. Single-agent tablets come in 1.25, 2.5, 3.75, 5, 7.5 & 10 mg strengths. Fixed-dose combinations pair it with hydrochlorothiazide, amlodipine, or perindopril.

Main End-Uses of Bisoprolol

Hypertension tablets take the largest share of bisoprolol volume. Doctors use it as a once-daily beta-blocker, often as a second-line agent after an ACE inhibitor, an ARB, or a calcium channel blocker. Its long half-life of 10 to 12 hours, oral bioavailability above 90 percent, and low food effect suit once-daily dosing. Generic 5 mg and 10 mg tablets carry most of this tonnage. Because the per-tablet price is low, formulators exert significant pressure on API pricing.

Chronic heart failure with reduced ejection fraction is the second large outlet. Bisoprolol is one of three beta-blockers, along with carvedilol and metoprolol succinate, with proven mortality benefit in this condition. The CIBIS-II trial established that benefit in the late 1990s. Heart-failure patients start on 1.25 mg and titrate upward through 2.5, 3.75, 5, and 7.5 mg over several weeks, which drives demand for the low strengths and for scored tablets. In practice, a heart-failure patient stays on bisoprolol for years.

Fixed-dose combinations form the third outlet. Bisoprolol with hydrochlorothiazide is sold in the US as Ziac and in Europe under several brands. Merck sells bisoprolol with amlodipine as Concor AM. Servier markets bisoprolol with perindopril as Cosyrel. Stable angina, rate control in atrial fibrillation, supraventricular tachycardia, and care after a heart attack add steady volume. In Japan, a bisoprolol transdermal tape gives a non-oral option for patients who cannot swallow tablets.

Bisoprolol Market Risks

Bisoprolol lies in a mature generic market, so price erosion is the main commercial risk. European tenders, Indian price controls, and US pharmacy buying groups squeeze margins at every step from API to tablet. A dozen qualified API sources compete for the same formulators. Any new low-cost entrant from India or China pushes prices lower again. Nitrosamine rules add a fresh layer of cost and risk. The FDA lists N-nitroso bisoprolol as a nitrosamine drug-substance-related impurity, with an acceptable intake of 1,500 ng per day. Formulators now ask API makers for nitrosamine risk assessments, nitrite data on excipients, confirmatory test results & change control records. A failed nitrosamine test can halt product sales across multiple markets simultaneously.

Bisoprolol manufacturing carries its own risks because the route handles hazardous & volatile reagents. Epichlorohydrin is a probable human carcinogen, a skin sensitizer & acutely toxic, and flammable. Isopropylamine boils near 32 degree Celsius and is highly flammable, so it needs closed handling and good condensers. The epoxide intermediate is a potential mutagenic impurity and has to be purged to trace levels. Dimer impurities form when one epoxide reacts with an already formed bisoprolol molecule. Secondary amine chemistry can also lead to N-nitroso bisoprolol if nitrite enters through water, recovered solvents, sodium hydroxide, or packaging. Most rejected lots trace back to dimer levels, residual epoxide, or out-of-limit related substances.

Bisoprolol Production Process and Main Cost Drivers

The bisoprolol production process is a short chemical synthesis of four main stages, from etherification through epoxide formation, amine ring-opening, and fumarate salt formation.

1. By Acid-Catalyzed Etherification, Epichlorohydrin Coupling and Isopropylamine Ring-Opening: The main inputs are 4-hydroxybenzyl alcohol, 2-isopropoxyethanol, an acid catalyst such as sulfuric acid or a sulfonic acid resin, epichlorohydrin, sodium hydroxide, isopropylamine, fumaric acid, toluene, methanol & acetone.

Bisoprolol synthesis starts by joining 4-hydroxybenzyl alcohol with 2-isopropoxyethanol under acid catalysis. The product is the key ether intermediate, 4-[(2-isopropoxyethoxy)methyl]phenol. 2-Isopropoxyethanol is used in excess and acts as both reagent & solvent. Older processes used sulfuric acid, high-temperature heating near 150 degree Celsius, or ion-exchange resins such as Amberlyst 15, Dowex 50, and IR 120. Yields sat near 65 percent, with self-condensation of the benzyl alcohol as the main side reaction. Piramal has patented a sulfuric acid-on-silica catalyst that runs at 25 to 60 degree Celsius and raises yield to 85 to 90 percent. Excess 2-isopropoxyethanol is recovered by vacuum distillation.

Next, the phenol is coupled with epichlorohydrin in the presence of sodium hydroxide to give the glycidyl ether epoxide. Some plants add a phase-transfer catalyst, a co-solvent such as toluene, or a slow base feed to limit hydrolysis, dimer, and chlorohydrin by-products. Excess epichlorohydrin is distilled & dried, assayed, and recycled. The epoxide is then opened with isopropylamine, usually in excess and often in methanol. This step gives bisoprolol base. Isopropylamine is stripped, condensed, and recovered for reuse. Dimer control at this stage depends on amine excess, temperature, dosing rate, and mixing.

To finish, the crude base is dissolved in acetone and treated with half an equivalent of fumaric acid. On cooling, bisoprolol fumarate crystallizes out. It is filtered, washed with cold acetone, dried under vacuum, milled, and sifted to the required particle size. QC covers assay, related substances, fumaric acid content, water, residual solvents, and nitrosamines. The main cost drivers are ether-step yield, epichlorohydrin and isopropylamine use, solvent recovery & final crystallization yield.

Main Factors Affecting Bisoprolol Production Cost

Bisoprolol production cost is shaped first by the etherification-step yield. That stage determines how much 4-hydroxybenzyl alcohol each kilogram of API consumes. A move from 65% to 85% yield cuts the main feedstock cost by about a quarter. Plants that buy the ether intermediate ready-made pay a margin to the intermediate maker instead. In most cases, the ether intermediate is the largest single raw material line.

Reagent excess is the next big factor. 2-Isopropoxyethanol, epichlorohydrin, and isopropylamine are all charged in excess to push conversion, limit dimers, and keep impurities low. Their recovery rate decides how much fresh reagent each batch needs. A plant with poor distillation loses money on every batch. On the utility side, steam for distillation and solvent stripping, chilled brine for condensers, vacuum, and nitrogen blanketing take most of the energy bill. Isopropylamine recovery needs good chilling because of its low boiling point.

Batch scale and plant utilization move unit cost too. Bisoprolol is a small-tonnage API, so it usually runs in campaigns on a multipurpose block. Changeover cleaning, swab testing, line clearance, and validation costs spread over a short campaign. QC adds real cost through HPLC impurity testing, residual solvent analysis, and LC-MS/MS nitrosamine testing. Effluent treatment for chlorinated organics and amine-bearing streams is a steady fixed charge. Regulatory maintenance of CEPs, DMFs, and Japanese regulatory filings is typically accounted for as an overhead cost.

Raw Materials for Bisoprolol Production Plant and its Procurement

Raw material sourcing for bisoprolol centers on four organic building blocks. 4-Hydroxybenzyl alcohol comes from phenol and formaldehyde chemistry or from reduction of 4-hydroxybenzaldehyde. 2-Isopropoxyethanol is a glycol ether made from isopropanol and ethylene oxide. Epichlorohydrin is a commodity chemical made from propylene via allyl chloride, or from glycerol in newer plants. Isopropylamine is made from isopropanol or acetone with ammonia. Fumaric acid, sodium hydroxide, toluene, methanol & acetone complete the bill of materials.

Many API makers skip the first step and buy the ether intermediate ready-made from Chinese or Indian intermediate makers. That choice cuts capital but adds supply risk and a margin layer. Epichlorohydrin prices track propylene, chlorine, caustic soda, and glycerol markets, so they swing with the petrochemical cycle. Isopropylamine has few global producers, which can tighten supply in a busy year. Intermediate purity matters a great deal. Phenolic impurities, residual benzyl alcohol, and dimeric ethers carried into the epoxide step become hard-to-remove related substances in the final API.

These sensitivities shape how a bisoprolol plant buys and qualifies inputs. Contracts specify assay, isomer, and phenolic impurity limits, water content & nitrite levels for each key material. Vendor qualification runs through audits, impurity-fate studies, and lot-by-lot testing. Incoming checks cover identity by IR, assay by GC or HPLC, water by Karl Fischer, and nitrite where relevant. Long-term deals with two qualified sources for the ether intermediate and epichlorohydrin are steady on both cost and timing. Locating the facility near a chemical cluster in Gujarat or Maharashtra can place most suppliers within one day’s freight distance.

Sustainability and Regulatory Requirements

Bisoprolol manufacture raises environmental and safety concerns around epichlorohydrin, volatile amines & chlorinated waste. Epichlorohydrin needs closed transfer, dedicated scrubbers, leak detection, and worker exposure monitoring. Isopropylamine vapors call for vent condensers, acid scrubbers, and closed sampling. Aqueous streams carry sodium chloride, glycol ethers, and amine salts that need biological treatment. Solvent recovery for toluene, methanol, and acetone cuts cost, emissions, and fresh solvent purchases. Spent catalyst, distillation residues, and filter cakes go to authorized incineration.

Regulatory obligations for bisoprolol follow from its status as a prescription cardiovascular API. In the US, makers file a Type II DMF and work under FDA cGMP per 21 CFR 210/211 and the USP bisoprolol fumarate monograph. In Europe, an EDQM Certificate of Suitability to the Ph. Eur. monograph is the normal route. ICH Q7 governs API manufacture, ICH M7 covers the epoxide and epichlorohydrin as potential mutagenic impurities, and ICH Q3C determines residual solvent limits. Nitrosamine risk assessments for N-nitroso bisoprolol are now expected by both the FDA and the EMA. Japanese supply needs a JDMF and conformity to the JP monograph.

CAPEX and OPEX for a Bisoprolol Production Plant

A bisoprolol plant is a small multipurpose API block rather than a dedicated large line. Capital starts with glass-lined and stainless steel reactors for etherification, epoxide formation, and amination. Each reactor needs reflux condensers, receivers, and vacuum. Distillation columns recover 2-isopropoxyethanol, epichlorohydrin, isopropylamine, and process solvents. The finishing area holds a crystallizer, centrifuge or agitated nutsche filter dryer, vacuum tray dryer, mill, and sifter in a classified zone. Utilities cover steam, chilled brine & cooling towers, nitrogen, purified water, scrubbers & an effluent treatment plant. On the QC side, a laboratory houses HPLC, GC headspace, Karl Fischer titrators, and LC-MS/MS for nitrosamines.

Bisoprolol operating cost starts with the ether intermediate or its two feedstocks, then epichlorohydrin, isopropylamine, and solvents. Utilities, GMP labor, QC testing, effluent treatment, packaging & freight make up the rest. Cost per kilogram depends on ether-step yield, reagent recovery, crystallization yield, and campaign length. The bisoprolol plant setup cost depends on reactor volume, distillation scope, containment for epichlorohydrin, and whether the plant makes the ether intermediate in-house. For a small-dose API, fixed QC and regulatory costs weigh more per kilogram than in bulk generics.

Plant Location and Investment Factors

A workable bisoprolol site sits inside an established API cluster with solvent supply, effluent capacity, and trained process chemists. India's clusters in Gujarat, Maharashtra, and Madhya Pradesh fit this profile well. Unichem and Ipca already run bisoprolol API in Maharashtra and Madhya Pradesh. Chinese sites offer close access to epichlorohydrin and the ether intermediate. European sites in Catalonia, Saxony, and other chemical regions serve buyers who want a short, audited, EU-inspected supply chain. The site needs a permit for epichlorohydrin storage and a full effluent plant.

For a bisoprolol project, the first decision is backward integration into the ether intermediate. Making it in-house cuts cost and supply risk but adds a reactor, a recovery column, more effluent, and more process validation. Buying it keeps capital lower, shortens validation, and speeds the start. The second decision is dedicated or campaign capacity. Bisoprolol demand is steady, but tonnage is modest, so most makers run it on shared equipment. A new entrant also needs a nitrosamine-clean process, a CEP, a US DMF, and stability data before buyers will qualify it.

Major Bisoprolol Producing Regions

India is the largest producing region for bisoprolol fumarate API today. Unichem, Ipca, Harman Finochem, Rusan Pharma, Medilux, and Piramal all hold a CEP for it. Indian makers combine low cost, deep intermediate supply & long experience with European filings. Europe keeps meaningful capacity through Moehs and Kinsy in Spain, and Arevipharma and Corden Pharma in Germany. These European sources supply buyers that value proximity, short lead times, and an EU inspection record. China holds CEPs through Beijing Jincheng Taier and Easton Biopharmaceuticals and also supplies many other intermediates. Taiwan Biotech adds an East Asian source with both a CEP and a US DMF. Finished-tablet output is spread widely, with large volumes made in India, Germany, Poland, and the UK.

Key Bisoprolol Producers

Merck KGaA

• Discovered bisoprolol at its Darmstadt research labs and still markets it worldwide as Concor.
• Sells the Concor family, including combinations with hydrochlorothiazide & amlodipine, across Europe, Latin America, the Middle East & Asia.
• Competes on originator brand trust, decades of clinical data & cardiology reach.
• Regulatory record covers national approvals across the EU, EU GMP & wide international registrations.

Unichem Laboratories

• Ranks among the established Indian makers of bisoprolol fumarate API and finished tablets.
• Runs USFDA-inspected API sites at Roha and Kolhapur in Maharashtra & Pithampur in Madhya Pradesh.
• Now sits inside the Ipca group, which took a controlling stake in the company.
• Holds an EDQM CEP & a US DMF for bisoprolol fumarate.

Ipca Laboratories

• Mumbai-based API and formulation maker with a strong cardiovascular portfolio.
• Produces APIs at its large chemical site in Ratlam, Madhya Pradesh, with deep backward integration.
• Competes on intermediate integration, scale & a low Indian cost base.
• Holds an EDQM CEP & a US DMF for bisoprolol fumarate.

Moehs Group

• Barcelona-based API maker that makes bisoprolol fumarate at its Catalana facility in Spain.
• Supplies the API in 25 kg fiber drums to the Ph. Eur., USP & JP monographs.
• Competes on EU manufacturing, wide regulatory coverage & a long beta-blocker track record.
• Documentation covers a CEP, EDMF, US DMF, JDMF & KDMF.

Arevipharma GmbH

• Makes around 40 APIs at Radebeul near Dresden, Germany, including cardiovascular products.
• Runs five production scales, up to several hundred tonnes per year under cGMP.
• Competes on German manufacturing, integrated development & a strong regulatory team.
• Holds an EDQM CEP & a US DMF for bisoprolol fumarate.

Piramal Pharma Solutions

• Supplies bisoprolol fumarate API from the Piramal Pharma network in India and the UK.
• Patented a sulfuric acid on silica route to the key ether intermediate with 85 to 90 percent yield.
• Competes on process chemistry, CDMO scale & multi-site capacity.
• Holds an EDQM CEP & a US DMF for bisoprolol fumarate.